Biotech Values

[oc631]

but are vectors commodities?

Quite the opposite in my opinion.

There is a paragraph in the interview that speaks of bringing down the cost manufacturing vectors yet I take the proposal as spurring innovation, adding greater focus on delivery.

The enterprise value of select companies will change dramatically once the IP is proven actionable, licensed, and accepted by industry as cutting edge.